Viking Therapeutics started at neutral by Citi
Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...
Viking Therapeutics price target lowered to $96 from $109 at B. Riley
B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...
January Recap: 13 Top Health Press Releases
Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...
Viking Therapeutics initiated with a Neutral at Citi
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...